Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
企業コードBJDX
会社名Bluejay Diagnostics Inc
上場日Nov 10, 2021
最高経営責任者「CEO」Mr. Neil (Indranil) Dey
従業員数7
証券種類Ordinary Share
決算期末Nov 10
本社所在地360 Massachusetts Avenue, Suite 203
都市ACTON
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号01720
電話番号19786310152
ウェブサイトhttps://bluejaydx.com/
企業コードBJDX
上場日Nov 10, 2021
最高経営責任者「CEO」Mr. Neil (Indranil) Dey
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし